Get the Stockscreener App
4.3393
31.45%
0.9693
Ironwood Pharmaceuticals Inc stock is traded at $4.3393, with a volume of 76.31M.
It is up +31.45% in the last 24 hours and up +26.57% over the past month.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.
See More
Previous Close:
$3.37
Open:
$4.595
24h Volume:
76.31M
Relative Volume:
22.09
Market Cap:
$706.03M
Revenue:
$400.57M
Net Income/Loss:
$9.21M
P/E Ratio:
108.48
EPS:
0.04
Net Cash Flow:
$146.36M
1W Performance:
+38.44%
1M Performance:
+26.57%
6M Performance:
+498.89%
1Y Performance:
+2.31%
1-Day Range:
$4.20
$5.78
1-Week Range:
$3.11
$5.78
52-Week Range:
$0.5271
$5.78
Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile
Name
Ironwood Pharmaceuticals Inc
Sector
Phone
617-621-7722
Address
100 SUMMER STREET, SUITE 2300, BOSTON, MA
Compare IRWD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRWD
Ironwood Pharmaceuticals Inc
|
4.34 | 548.23M | 400.57M | 9.21M | 146.36M | 0.04 |
|
ZTS
Zoetis Inc
|
125.41 | 55.45B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.62 | 49.25B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.02 | 45.02B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.64 | 35.81B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
490.48 | 20.98B | 3.08B | 1.24B | 1.07B | 25.61 |
Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-25 | Downgrade | Jefferies | Buy → Hold |
| Apr-15-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-14-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Sep-09-24 | Initiated | Leerink Partners | Market Perform |
| Aug-08-24 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Jan-17-24 | Initiated | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Wells Fargo | Overweight |
| Nov-09-23 | Initiated | Jefferies | Buy |
| Sep-28-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-02-22 | Initiated | CapitalOne | Overweight |
| Apr-22-22 | Initiated | Piper Sandler | Overweight |
| Sep-30-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-17-20 | Initiated | Northland Capital | Outperform |
| Jul-10-19 | Resumed | Credit Suisse | Neutral |
| Mar-27-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-25-19 | Upgrade | H.C. Wainwright | Sell → Neutral |
| Jan-24-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-07-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| Nov-07-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-23-18 | Initiated | H.C. Wainwright | Sell |
| May-09-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-05-18 | Downgrade | BofA/Merrill | Buy → Underperform |
| Dec-06-17 | Downgrade | Mizuho | Buy → Neutral |
| Jul-21-17 | Downgrade | JP Morgan | Overweight → Neutral |
| May-03-17 | Initiated | Wells Fargo | Outperform |
| Apr-07-17 | Reiterated | Mizuho | Buy |
| Feb-22-17 | Reiterated | Barclays | Equal Weight |
| Nov-04-16 | Reiterated | Mizuho | Buy |
| Oct-24-16 | Reiterated | Wedbush | Neutral |
| Oct-10-16 | Reiterated | Mizuho | Buy |
| Sep-27-16 | Reiterated | WallachBeth | Hold |
View All
Ironwood Pharmaceuticals Inc Stock (IRWD) Latest News
Ironwood boosts outlook on AbbVie's Linzess (update) (IRWD) - Seeking Alpha
Ironwood Pharmaceuticals: Market Response to Legal Settlement - StocksToTrade
Ironwood Pharmaceuticals (NASDAQ:IRWD) Hits New 12-Month HighHere's Why - MarketBeat
Ironwood Pharmaceuticals Inc. (IRWD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Ironwood Pharmaceuticals, Baidu, Vertiv Holdings And Other Big Stocks Moving Higher On Friday - Benzinga
Why Did Ironwood Pharmaceuticals Stock Skyrocket Today? - Stocktwits
Why Is IRWD Stock Soaring Over 30% Premarket? 2026 Revenue Outlook Beats Estimates - Tokenist
Ironwood (IRWD) Focuses on Financial Growth and Drug Development - GuruFocus
Ironwood Pharmaceuticals, Inc. Maintains Earnings Guidance for Year 2025 and Provides Earnings Guidance for Year 2026 - marketscreener.com
Ironwood Pharmaceuticals (IRWD) Projects Strong Revenue Growth f - GuruFocus
Ironwood Pharma Provides FY26 Outlook, Maintains Full Year Outlook - Nasdaq
Ironwood forecasts 2026 LINZESS sales to exceed $1.1 billion - Investing.com
Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance - TradingView — Track All Markets
Why is Ironwood (IRWD) up 24.9% since last earnings report? - MSN
Ironwood Pharmaceuticals expresses gratitude and drives GI health progress - Traders Union
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Up 4.8%Still a Buy? - MarketBeat
Ironwood Pharma (NASDAQ:IRWD) Nasdaq composite Biotech Watch - Kalkine Media
Ironwood Pharmaceuticals (NASDAQ:IRWD) Share Price Crosses Above Two Hundred Day Moving AverageHere's Why - MarketBeat
Ironwood Pharmaceuticals' VectivBio Settles Ferring Lawsuit Through License Amendment - marketscreener.com
Boston biotech settles lawsuit alleging misappropriation of GLP-2 analog intellectual property - The Business Journals
Ironwood gains after settling Ferring lawsuit (IRWD:NASDAQ) - Seeking Alpha
Ironwood Pharmaceuticals amends license deal with Ferring, settles litigation By Investing.com - Investing.com UK
Ironwood Pharmaceuticals, Inc.(NasdaqGS:IRWD) added to S&P Biotechnology Select Industry Index - marketscreener.com
How Ironwood Pharmaceuticals Inc. (I76) stock reacts to Fed tighteningOil Prices & Free Accurate Trade Setup Notifications - Улправда
Geopolitics Watch: Why Ironwood Pharmaceuticals Inc. stock is rated strong buyAnalyst Downgrade & Stepwise Trade Signal Guides - Улправда
Why Ironwood Pharmaceuticals Inc. stock is rated strong buyJuly 2025 Update & High Accuracy Trade Signal Alerts - Улправда
Ironwood Pharmaceuticals Earnings Notes - Trefis
Published on: 2025-12-19 06:52:33 - Улправда
Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Down 3.7%Here's Why - MarketBeat
What drives Ironwood Pharmaceuticals Inc stock priceMarket Entry Points & High Yield Portfolio Growth - earlytimes.in
Ironwood Pharmaceuticals (IRWD) director and 10% owner reports new share grant - Stock Titan
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Ironwood Pharmaceuticals announces workforce reduction - MSN
Ironwood Pharma Board Member Resigns for New Role - MSN
Ironwood Pharma drops 7% as FY 2025 revenue guidance below consensus - MSN
Armistice Capital LLC Acquires 2,450,000 Shares of Ironwood Pharmaceuticals, Inc. $IRWD - MarketBeat
Why Is Ironwood (IRWD) Up 24.9% Since Last Earnings Report? - sharewise.com
Ironwood Pharmaceuticals (NASDAQ:IRWD) Trading Up 6%What's Next? - MarketBeat
Ironwood Pharmaceuticals (IRWD) price target increased by 38.89% to 2.55 - MSN
Ironwood Pharma’s LINZESS® Price Set by HHS - MSN
Can Ironwood Pharmaceuticals Stock Recover If Markets Fall? - Trefis
Ironwood Pharmaceuticals (IRWD) Price Target Increased by 38.89% to 2.55 - Nasdaq
Can Ironwood Pharmaceuticals Stock Hold Up When Markets Turn? - Trefis
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Down 5%Time to Sell? - MarketBeat
Is Ironwood Pharmaceuticals Inc. (I76) stock cheap by valuation metricsOptions Play & Scalable Portfolio Growth Ideas - Newser
Can Ironwood Pharmaceuticals Inc. stock sustain institutional interestProfit Target & Fast Gaining Stock Strategy Reports - Newser
Zacks Research Analysts Increase Earnings Estimates for IRWD - MarketBeat
Why Ironwood Pharmaceuticals Inc. (I76) stock could be next leaderJuly 2025 Macro Moves & Community Verified Swing Trade Signals - Newser
How dovish Fed policy supports Ironwood Pharmaceuticals Inc. (I76) stockRecession Risk & Weekly High Return Forecasts - Newser
Irritable Bowel Syndrome (IBS) Treatment Market Competition Analysis 2025: How Players Are Shaping Growth - EIN News
IRWD SEC FilingsIronwood 10-K, 10-Q, 8-K Forms - Stock Titan
Ironwood Pharmaceuticals Inc Stock (IRWD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.43%
2.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):